CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerations

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Feb 2025: Trial registered, NCT06835179

The trials

NCT06835179: SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

State
Not started
Phase
Phase 2
People
28 planned
Started
Feb 2025
Primary completion
Feb 2027
Arms
Experimental group
Results
None posted
  1. 19 Feb 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.